On this page you will find a review of the circulation of the coronavirus SARS‑CoV‑2 in the Netherlands during the 2025/2026 respiratory season. We describe how frequently the virus occurred, how this compared to previous seasons, and which variants were dominant.

Because most respiratory infections occur mainly in winter, the figures are presented per respiratory season or respiratory year. A respiratory season runs from week 40 of one year up to and including week 20 of the following year. A respiratory year runs from week 40 of one year up to and including week 39 of the following year. This report mainly concerns the respiratory season 2025/2026, the period from week 40 of 2025 up to and including week 20 of 2026. In some cases, data are also presented for the period from week 21 up to and including week 39 of 2025. That is the period preceding the 2025/2026 season. More background information on the different surveillance sources can be found in the document “Background and methods of respiratory surveillance 2025/2026”. 

Low SARS-CoV-2 levels 

From mid-September (week 38) to the end of October (week 44) 2025, there was a slight increase in circulation of the coronavirus SARS-CoV-2 in the Netherlands. After week 41, just after the start of the 2025/2026 respiratory season, the amount of SARS-CoV-2 decreased again in most sources. In the different sources, the level of this increase from mid-September to the end of October 2025 was lower or similar compared to the increase in autumn 2024. From early 2026 until the end of the respiratory season, circulation of the virus remained at a low level.

The amount of SARS-CoV-2 particles in wastewater surveillance during the increase in autumn 2025 was lower than during the increase in autumn 2024. The highest weekly proportion of Infectieradar participants reporting a positive self-test for coronavirus in autumn 2025 (1.5%) was the same as in autumn 2024 (1.5%). In specimens taken in general practices participating in the Nivel Primary Care Database, SARS-CoV-2 was detected relatively often during the increase in autumn 2025 compared with other periods in 2025/2026.

The number of people with respiratory symptoms outside the respiratory season is much lower than during the respiratory season. The number of specimens taken outside this season is therefore also low. Because SARS-CoV-2 also circulates outside the respiratory season, the weekly percentage of specimens that test positive for this virus fluctuates strongly in this period. This is visible in the last week of July 2025 (week 31). Then, a high percentage of specimens tested positive for SARS-CoV-2, but this was based on only 3 specimens.

During the increase in autumn 2025, a maximum of 380 SARS-CoV-2 detections per week was reported in the virological laboratory surveillance (week 41). Based on laboratories that report the number of tests performed as well as the number of positive results, the percentage of specimens that test positive for SARS-CoV-2 can also be reported. The highest weekly percentage positive during the increase in autumn 2025 was 12.4% (week 40 and 41). Both the total number and the percentage of positive tests were lower in autumn 2025 than in autumn 2024.

Hospital admissions and mortality due to SARS-CoV-2

From 2025 onwards, RIVM receives data via the National Intensive Care Evaluation (NICE) Foundation on the number of patients who were admitted to an intensive care unit (ICU) because of an acute respiratory infection (Severe Acute Respiratory Infection, or SARI). SARI admissions can have different causes, for example pneumonia due to a bacterium or virus, or infection with influenza virus, RS-virus or SARS-CoV-2. In data from 44 ICUs it was seen that the weekly number of SARI-ICU admissions increased slightly in September 2025 (from week 37) and remained at a low level during the SARS-CoV-2 increase in autumn 2025 (week 38–44). During the SARS-CoV-2 increase in autumn 2025, there was no excess mortality.

Variants of coronavirus SARS-CoV-2

RIVM monitors which SARS-CoV-2 variants are circulating and what characteristics they have. Within this SARS-CoV-2 pathogen surveillance, sequence analyses are carried out on 1) specimens sent in for analysis by a large number of clinical diagnostic laboratories in the Netherlands, 2) specimens from the Nivel Primary Care Database  from people with an acute respiratory infection at general practices, and 3) specimens from Infectieradar from people in the general population with a self‑reported acute respiratory infection.

Since 2024, SARS-CoV-2 variant JN.1 and various subvariants and recombinants of JN.1 have been dominant in the Netherlands. From week 21 of 2025 up to and including week 20 of 2026, KP.3, XEC, NB.1.8.1, LP.8.1 and XFG were most frequently seen in the SARS-CoV-2 pathogen surveillance. From early July 2025 (week 28) subvariant XFG was dominant. In autumn 2025, XFG accounted for 80–90% of detections in the pathogen surveillance. Since summer 2025, variant BA.3.2 has been detected. At first this variant was seen only sporadically, but from mid‑November 2025 (week 46) the share of BA.3.2, and especially subvariant BA.3.2.2, increased. In spring 2026, XFG and BA.3.2 together were most common in the Netherlands. Because only few specimens have been available for typing since early February 2026 (week 7) due to the low level of circulation of SARS-CoV-2, it is unclear whether one of these variants will increase in proportion. Although BA.3.2 and its subvariants differ antigenically from earlier variants and from the current vaccine, it is expected that the current vaccines still provide protection against severe disease (WHO).

COVID-19 vaccination

The autumn round of COVID-19 vaccination for people aged 60 years and older and specific risk groups ran from 15 September to 5 December 2025. The vaccination coverage for all people aged 60 years and older in this autumn round was 41.7%, and was highest in those aged 80–84 years (55.8%). The vaccine effectiveness of the 2025 autumn round against SARS-CoV-2 infection in people aged 60 years and older was 36% (95% CI: 25–45), based on data from the VASCO study. Estimates of vaccine effectiveness of the 2025 autumn round against hospital admission are not yet available. For the 2024 autumn round, vaccine effectiveness against hospital admission for people aged 60 years and older was estimated at 55–62% in the first 3 months after vaccination.

Figures on coronavirus SARS-CoV-2

Coronavirus SARS-CoV-2 in specimens from laboratories – Virological laboratory surveillance

Number of positive specimens

Skip chart 'Coronavirus SARS-CoV-2 in specimens from laboratories' and go to datatable

Source: virological laboratory surveillance from the Dutch Working Group for Clinical Virology (NWKV).
Footnote: This data is owned by laboratories participating in the virological laboratory surveillance (Virologische Weekstaten), represented by the board of the Dutch Working Group for Clinical Virology (NWKV). The database is managed by RIVM. Further use of the data is not allowed without permission. Permission for use of the data may be requested by contacting virweekstaten@rivm.nl.
Note: The data are shown from week 12 of 2023 onwards, after the closure of the Public Health Service (GGD) testing sites.

Percentage of positive specimens

Skip chart 'Coronavirus SARS-CoV-2 in specimens from laboratories' and go to datatable

Source: virological laboratory surveillance from the Dutch Working Group for Clinical Virology (NWKV).
Footnote: This data is owned by laboratories participating in the virological laboratory surveillance (Virologische Weekstaten), represented by the board of the Dutch Working Group for Clinical Virology (NWKV). The database is managed by RIVM. Further use of the data is not allowed without permission. Permission for use of the data may be requested by contacting virweekstaten@rivm.nl.